Cost-effectiveness of atenolol compared to propranolol as first-line treatment of infantile haemangioma: A pilot study

Propranolol is the first-line agent for the treatment of infantile haemangioma (IH). Due to its non-selective beta blockade respiratory adverse events are commonplace. Atenolol is a selective beta-1 antagonist and is a second line for patients with a significant respiratory history or those intolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Sasha, Hassan, Deniz, Jakeman, Molly, Breuning, Eleonore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240956/
https://www.ncbi.nlm.nih.gov/pubmed/35784377
http://dx.doi.org/10.1016/j.jpra.2022.05.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240956/
https://www.ncbi.nlm.nih.gov/pubmed/35784377
http://dx.doi.org/10.1016/j.jpra.2022.05.010

Ejemplares similares